Inglis Tiffany Eul Davis sold $16K of SERA
Inglis Tiffany Eul Davis (Chief Medical Officer) sold 8,024 shares of SERA PROGNOSTICS, INC. (SERA) at $2.03 on 2026-10-12.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider trading record for SERA, which can influence sentiment but does not, by itself, change company fundamentals.
Market read
Traders may briefly reassess sentiment around SERA due to insider selling, but the small dollar amount limits tradable impact.
What to watch
No context is provided on total insider holdings, diversification needs, or whether other insiders sold/bought around the same period.
Background
The article is an SEC Form 4 insider transaction disclosure for SERA Prognostics, Inc.
Ticker impact
SEC Form 4 shows CMO Inglis Tiffany Eul Davis sold 8,024 shares at $2.0300 on 2026-10-12, worth about $16.3K, with no 10b5-1 plan.
Likely limited downside pressure as traders note insider selling, but impact should be muted given the small transaction value.
The filing is primary-source and directly tied to SERA, but the transaction size ($16.3K) is modest and the article provides no accompanying operational or guidance catalyst.
Market effects
Minimal, as this is a single-company insider transaction with no sector-wide signal.
None indicated.
None indicated.
Counterpoint
The sale may be routine liquidity management, and the absence of a 10b5-1 plan does not necessarily imply negative fundamentals.
Key entities
- issuerSERA Prognostics, Inc.
Company whose insider transaction was disclosed on Form 4.
- insiderInglis Tiffany Eul Davis
Chief Medical Officer who sold shares in an open-market transaction.
